



Alpa Laboratories Ltd.

33/2, Pigdamber A.B. Road - 453 446 Distt. Indore - (M.P.) India

Phone No. : +91-731- 429 4567 Fax No. : +91-731- 429 4444

Email : mail@alpalabs.in

CIN : L85195MP1988PLC004446

12th February, 2021

To,
Listing Department,
BSE Limited.
Rotunda Building, P J Towers
Dalal Street, Fort,
Mumbai – 400 001
Scrip Code: 532878

To,
Listing Department,
National Stock Exchange of India Limited.
'Exchange Plaza', C-1, Block G,
Bandra - Kurla Complex,
Bandra (E), Mumbai – 400 051
Scrip Code: ALPA

Subject: Outcome of Board Meeting under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir/ Madam,

This is with reference to our letter dated 01st February, 2021 in relation to the intimation of board meeting; this is to inform you that the Board of Directors of the Company at its meeting held today at 4.00 p.m. at registered office of the Company situated at 33/2, A.B. Road Pigdamber Rao, Indore MP 453446 IN. The Board inter-alia has approved the following matter:

1. Approval of the Un-Audited Standalone & Consolidated Financial Results of the Company for Quarter ended on 31st December, 2020 with Limited Review Report from the Statutory Auditor of the Company.

Meeting Start Time 04:00 PM

Meeting End Time: 07:00 PM

This is for the information and record of the exchange and members thereof;

You are requested to take the same on records.

For ALPA LABORATORIES LIMITED

Mahendra
Mahendra Singh Chawla
Director
DIN-00362058





INDEPENDENT AUDITOR'S LIMITED REVIEW REPORT ON STANDALONE QUARTERLY FINANCIAL RESULTS PURSUANT TO REGULATIONS 33 OF THE SEBI LODR REGULATIONS, 2015

To the Board of Directors of **ALPA LABORATORIES LIMITED**

1. We have reviewed the accompanying statement of unaudited standalone financial results of **ALPA LABORATORIES LIMITED** for the quarter ended **December 31, 2020** and year to date from April 01,2020 to December 31, 2020 attached herewith being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation,2015, as amended. ('Listing Agreement')
2. This statement which is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We have conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulation, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Anuradha Ratnaparkhi & Associates.

Chartered Accountants

Firm Registration No.023451C

Anuradha Ratnaparkhi

Proprietor

Membership Number:075412

UDIN- 21075412AAAAAC1937

Place: Indore

Date: February 12,2021

ALPA LABORATORIES LIMITED

33/2 PIGDAMBER, A.B. ROAD, RAU INDORE (M.P.)

453446

Financial Results for Quarter ended 31st December 2020

(Rs. in lacs except EPS)

I. Statement of Profit and Loss - Standalone and Consolidated

Particular	STANDALONE RESULTS					
	Quarter Ended			Nine months ended		Year Ended
	31-Dec-20	30-Sep-20	31-Dec-19	31-Dec-20	31-Dec-19	31-Mar-20
	Unaudited					Audited
1. Income						
a) Revenue from operations	3,316.42	2,310.79	2,412.64	7,256.67	6,780.63	8,596.91
b) Other Income	117.80	86.65	116.41	376.95	219.68	296.67
1. Total income from operations (net) (a+b)	3,434.22	2,397.44	2,529.05	7,633.62	7,000.31	8,893.58
2. Expenses						
a) Cost of materials consumed	1,498.60	1,671.03	1,230.82	3,939.51	4,046.26	4,948.01
b) Purchases of stock-in-trade	80.99	215.09	20.75	361.14	115.16	193.83
c) Changes in inventories of finished products, work in progress and stock in trade	406.37	(432.27)	184.32	22.30	82.52	(42.41)
d) Employee benefit expenses	372.67	277.65	292.28	899.36	853.30	1,182.43
e) Finance costs	2.55	3.49	2.81	8.32	16.26	19.94
f) Depreciation and amortization expenses	30.65	28.97	28.68	87.73	81.03	114.20
g) Other expenses						
Manufacturing & Operating	134.31	138.14	105.04	353.25	320.17	427.09
Others	530.88	266.53	355.29	1,032.98	901.12	1,542.76
Total expenses	3,057.02	2,168.63	2,219.99	6,704.59	6,415.82	8,385.85
3. Profit/(Loss) before exceptional items and tax (1-2)	377.20	228.81	309.06	929.03	584.49	507.73
4. Exceptional Items	-	-	-	-	-	-
5. Profit/ Loss(-) before tax (3+/-4)	377.20	228.81	309.06	929.03	584.49	507.73
6. Tax (Expenses)/ Benefit						
Current tax	-	-	-	-	-	(190.00)
Deferred tax	-	-	-	-	-	75.48
Tax Related to Earlier Years	-	-	-	-	-	14.60
7. Profit/ Loss(-) for the period (5-/+6)	377.20	228.81	309.06	929.03	584.49	407.81
8. Other Comprehensive Income						
(i) (a) Items that will not be reclassified to profit or loss	0.55	0.54	0.50	0.55	2.18	2.49
(b) Tax expense/(benefit) on items that will not be reclassified to profit or loss	-	-	-	-	-	-
(ii) (a) Items that will be reclassified to profit & loss	-	-	-	-	-	-
(b) Tax expense/(benefit) on items that will be reclassified to profit or loss	-	-	-	-	-	-
Total Other comprehensive (loss)/ income (net of tax)	0.55	0.54	0.50	0.55	2.18	2.49
9. Total comprehensive income for the period (7+8)	377.75	229.35	309.56	929.58	586.67	410.30
10. Paid-up equity share capital (Face Value Rs. 10 Each)	2,104.06	2,104.06	2,104.06	2,104.06	2,104.06	2,104.06
11. Other equity (excluding revaluation reserve)	-	-	-	-	-	8,918.90
12. Debenture Redemption Reserve	-	-	-	-	-	-
13. Basic and Diluted Earnings per share after extraordinary items (not annualized)	1.80	1.09	1.47	4.42	2.79	1.95

For Alpa Laboratories Ltd.

Mahendra
 Mahendra Singh Chawla
 Director
 DIN-00362058



INDEPENDENT AUDITOR'S LIMITED REVIEW REPORT ON CONSOLIDATED QUARTERLY FINANCIAL RESULTS PURSUANT TO REGULATIONS 33 OF THE SEBI LODR REGULATIONS, 2015

To the Board of Directors of **ALPA LABORATORIES LIMITED**

1. We have reviewed the accompanying statement of unaudited consolidated financial results of **ALPA LABORATORIES LIMITED** for the quarter ended **December 31, 2020** and year to date from April 01, 2020 to December 31, 2020 attached herewith being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, as amended. ('Listing Agreement')
2. This statement which is the responsibility of the Company's Management and has been approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.
3. We have conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial information performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. The Statement includes the results of the Company's wholly owned Subsidiary.
5. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulation, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Anuradha Ratnaparkhi & Associates.

Chartered Accountants

Firm Registration No.023451C

Anuradha Ratnaparkhi

Proprietor

Membership Number:075412

UDIN- 21075412AAAAAD2307



Place: Indore

Date: February 12, 2021

ALPA LABORATORIES LIMITED

33/2 PIGDAMBER, A.B. ROAD, RAU INDORE (M.P.)

453446

Financial Results for Quarter ended 31st December 2020

(Rs. in lacs except EPS)

Particular	CONSOLIDATED RESULTS					
	Quarter Ended			Nine months ended		Year Ended
	31-Dec-20	30-Sep-20	31-Dec-19	31-Dec-20	31-Dec-19	31-Mar-20
	Unaudited					Audited
1. Income						
a) Revenue from operations	3,316.42	2,310.79	2,412.64	7,256.67	4,367.99	8,596.91
b) Other Income	112.83	89.93	116.04	373.35	97.30	291.24
1. Total income from operations (net) (a+b)	3,429.26	2,400.72	2,528.68	7,630.03	4,465.28	8,888.15
2. Expenses						
a) Cost of materials consumed	1,498.60	1,671.03	1,230.82	3,939.51	2,815.45	4,948.01
b) Purchases of stock-in-trade	80.99	215.09	20.75	361.14	94.41	193.83
c) Changes in inventories of finished products, work in progress and stock in trade	406.37	(432.27)	184.32	22.30	(101.80)	(42.41)
d) Employee benefit expenses	372.67	277.65	292.28	899.36	561.03	1,182.43
e) Finance costs	1.81	2.86	2.81	6.95	13.45	19.62
f) Depreciation and amortization expenses	30.65	28.97	79.24	87.73	153.48	316.45
g) Other expenses						
Manufacturing & Operating	134.31	138.14	105.04	353.25	215.12	427.09
Others	530.88	266.53	355.45	1,032.99	554.26	1,552.38
Total expenses	3,056.28	2,168.00	2,270.71	6,703.23	4,305.40	8,597.40
3. Profit/(Loss) before exceptional items and tax (1-2)	372.97	232.72	257.97	926.79	159.89	290.75
4. Exceptional Items	-	-	-	-	-	-
5. Profit/ Loss(-) before tax (3+/-4)	372.97	232.72	257.97	926.79	159.89	290.75
6. Tax (Expenses)/ Benefit						
Current tax	-	-	-	-	-	(190.00)
Deffered tax	-	-	-	-	-	75.48
Tax Related to Earlier Years	-	-	-	0.15	-	9.11
7. Profit/ Loss(-) for the period (5-/+6)	372.97	232.72	257.97	926.94	159.89	185.34
8. Other Comprehensive Income						
(i) (a) Items that will not be reclassified to profit or loss	-	0.54	0.50	1.04	1.67	2.49
(b) Tax expense/(benefit) on items that will not be reclassified to profit or loss	-	-	-	-	-	-
(ii) (a) Items that will be reclassified to profit & loss	-	-	-	-	-	-
(b) Tax expense/(benefit) on items that will be reclassified to profit or loss	-	-	-	-	-	-
Total Other comprehensive (loss)/ income (net of tax)	-	0.54	0.50	1.04	1.67	2.49
9. Total comprehensive income for the period (7+8)	372.97	233.26	258.47	927.98	161.56	187.82
10. Paid-up equity share capital (Face Value Rs. 10 Each)	2,104.06	2,104.06	2,104.06	2,104.06	2,104.06	2,104.06
11. Other equity (excluding revaluation reserve)	-	-	-	-	-	7,933.20
12. Debenture Redemption Reserve	-	-	-	-	-	-
13. Basic and Diluted Earnings per share after extraordinary items (not annualized)	1.77	1.11	1.23	4.41	0.77	0.89

Notes -

- The above results have been subjected to Limited Review by the Statutory Auditors, reviewed by Board Audit Committee and have been approved by the Board of Directors at its meeting today.
- This statement has been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under Section 133 of the Companies Act, read with rule 3 of the Companies (Indian accounting Standards) Rules, 2015 and Companies (Indian Accounting Standards) Accounting Rules, 2016
- The Company is operating in the single segment of Drugs & Chemicals.
- The Provision for Tax may not have been made for the partial/ unaudited periods.
- The Figures of Previous Year/ Periods may have been regrouped/ reclassified wherever necessary.
- Covid-19 pandemic has been rapidly spreading throughout the world, including India. Government in India has taken significant measures to curb the spread of the virus including imposing mandatory lockdowns and restrictions in activities. The Company is monitoring the situation closely taking into account directives from the Governments. Management believes that it has taken into account all the possible impacts of known events arising from COVID-19 pandemic and the resultant lockdowns in the preparation of the financial statements including but not limited to its assessment of Company's liquidity and going concern, recoverable values of its property, plant and equipment, intangible assets, intangible assets under development and the net realisable values of other assets. However, given the effect of these lockdowns on the overall economic activity the assessment of COVID-19 on the abovementioned financial statement captions is subject to significant estimation uncertainties given its nature and duration and, accordingly, the actual impacts in future may be different from those estimated as at the date of approval of these financial results. The Company will continue to monitor any material changes to future economic conditions and consequential impact on its financial results.

For Alpa Laboratories Ltd.

Mahendra Singh Chawla
 Mahendra Singh Chawla
 Director
 DIN-00362058